- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.03. | FDA approves BeiGene's Tevimbra plus chemo for oesophageal cancer | ||
| 05.03. | MWC Barcelona 2025: Maximizing 5G network value in the age of AI | ||
| 04.03. | Antibody drug conjugates: Tackling the unsolved challenges with novel technologies | ||
| 04.03. | Callio raises $187m for proof-of-concept for dual-payload ADC | ||
| 04.03. | Are European biopharma manufacturers 'nearshoring'? | ||
| 04.03. | Machine learning adoption into supply chain management on the horizon | ||
| 04.03. | Reflecting on a milestone year for cell and gene therapies | ||
| 04.03. | Genentech wins FDA approval for second stroke treatment | ||
| 04.03. | MWC Barcelona 2025: Huawei unveils global showcases alongside customers and launches 10 industry solutions with partners | ||
| 03.03. | Using artificial intelligence to enhance regenerative medicine | ||
| 03.03. | Novo Nordisk and AI-driven Gensaic enter into $354m cardiometabolic deal | ||
| 03.03. | EC approves Bavarian Nordic's chikungunya vaccine marketing | ||
| 03.03. | Ryoncil, the first FDA-approved mesenchymal stromal cell therapy | ||
| 03.03. | AbbVie enters obesity space with $2.3bn Gubra deal | ||
| 03.03. | Leading Artificial Intelligence (AI) Companies in Pharma | ||
| 03.03. | BridgeBio Oncology and Helix enter definitive merger agreement | ||
| 03.03. | Magnet Biomedicine and Lilly link for molecular glue therapeutics | ||
| 28.02. | CHMP recommends AbbVie's Rinvoq be approved for adult GCA | ||
| 28.02. | Rare disease treatments skipping UK patients largely due to costs, survey shows | ||
| 28.02. | Why pharma is still far from a treatment for galactosemia | ||
| 28.02. | Medigene and EpimAb to develop T cell engagers for solid tumours | ||
| 28.02. | FDA accepts Sobi's Gamifant application for HLH/MAS treatment | ||
| 28.02. | Exelixis focuses on future growth despite COSMIC-313 trial challenges | ||
| 28.02. | Alltrna plans to tackle rare diseases using tRNA-based therapies | ||
| 27.02. | New EU trial regulations could expedite approvals and address shortages |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
